Blastoschizomyces capitatus represents an emerging fungal pathogen in acute leukemia patients. The susceptibility to amphotericin B, 5-fluorocytosine, ketoconazole and fluconazole of nine clinical isolates was evaluated. A specific medium (high resolution medium) was used for testing fluconazole. This agent and 5-fluorocytosine were at least four- to eight-fold more active than amphotericin B and ketoconazole against all isolates but one.
Venditti, M., Posteraro, B., Morace, G., Martino, P., In-vitro comparative activity of fluconazole and other antifungal agents against Blastoschizomyces capitatus, <<JOURNAL OF CHEMOTHERAPY>>, 1991; 3 (1): 13-15. [doi:10.1080/1120009X.1991.11739056] [http://hdl.handle.net/10807/13807]
In-vitro comparative activity of fluconazole and other antifungal agents against Blastoschizomyces capitatus
Posteraro, Brunella;
1991
Abstract
Blastoschizomyces capitatus represents an emerging fungal pathogen in acute leukemia patients. The susceptibility to amphotericin B, 5-fluorocytosine, ketoconazole and fluconazole of nine clinical isolates was evaluated. A specific medium (high resolution medium) was used for testing fluconazole. This agent and 5-fluorocytosine were at least four- to eight-fold more active than amphotericin B and ketoconazole against all isolates but one.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
